MoleculeMind is an AI-driven biotech company that utilizes advanced algorithms for high-precision protein structure prediction, directed mutagenesis, and de novo protein design. The platform accelerates drug development and industrial applications by enabling rapid identification and optimization of proteins, addressing inefficiencies in traditional biotechnological processes.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional protein design and optimization methods are slow, expensive, and often inefficient, hindering the development of new drugs, industrial enzymes, and advanced materials. Identifying proteins with desired properties requires extensive lab work and high-throughput screening, limiting the speed and scope of biotechnological innovation.
Solution
MoleculeMind offers an AI-powered platform that accelerates protein design and optimization through high-precision protein structure prediction, directed mutagenesis, and de novo protein design. The platform leverages advanced algorithms to rapidly identify and optimize proteins with desired properties, reducing the time and cost associated with traditional methods. By enabling the computational design of novel proteins, MoleculeMind facilitates innovation across drug discovery, industrial biotechnology, and materials science. The AI platform helps researchers quickly translate lab research into industrial applications.
Target Audience
MoleculeMind's primary customers are biotechnology companies, pharmaceutical firms, and research institutions involved in drug discovery, enzyme engineering, and materials development.
Features
- AI-driven protein structure prediction for accurate modeling of protein conformations
- Directed mutagenesis tools for modifying existing proteins to enhance specific properties
- De novo protein design capabilities for creating novel proteins with custom functions
- Large-scale sampling and iterative optimization algorithms to improve molecular properties such as binding affinity and ADMET
- High-throughput virtual screening for identifying promising drug candidates
- AI-based prediction of protein function and mutation probabilities